DHODH and COVID-19: One DHODH inhibitor, IMU-838 (Vidofludimus calcium), was further clinically evaluated for COVID-19 therapy in hospitalized patients and was found effective according to secondary criteria, e.g. time to clinical improvement or viral burden (CALVID-1, trial identifier NCT04379271; NCT04516915).